Advertisement
Advertisement
U.S. markets close in 5 hours 23 minutes
Advertisement
Advertisement
Advertisement
Advertisement

Nascent Biotech, Inc. (NBIO)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.3040+0.0030 (+1.00%)
As of 09:41AM EDT. Market open.
Advertisement
Full screen
Loading interactive chart...
  • ACCESSWIRE

    Nascent Biotech Completes Fourth Cohort in Phase 1 Human Trial for Primary and Metastatic Brain Cancer

    Nascent Biotech, Inc. (OTCQB:NBIO) ("Nascent Biotech", "Nascent", or the "Company"), a clinical-stage biotechnology Company pioneering the development of monoclonal antibodies targeting various cancer types, announced today the completion of the Fourth Cohort in dosing patients in the Company's Phase I trial to evaluate Pritumumab ("PTB") as a treatment for Brain Cancer, including Primary and metastatic Brain Tumors.

  • ACCESSWIRE

    Nascent Biotech Receives Notice of Allowance from USPTO for Issuance of Additional Patent

    Nascent Biotech, Inc. (OTCQB:NBIO) ("Nascent Biotech", "Nascent", or the "Company"), a clinical-stage biotechnology Company pioneering the development of monoclonal antibodies targeting treatment of various cancers and viral infections, is pleased to announce that the United States Patent and Trademark Office (the "USPTO") has issued a Notice of Allowance for claims related to the Company's lead candidate Pritumumab.

  • ACCESSWIRE

    Nascent Biotech Completes Third Cohort in Phase 1 Human Trial for Primary and Metastatic Brain Cancer

    VERO BEACH, FL / ACCESSWIRE / June 7, 2022 / Nascent Biotech, Inc. (OTCQB:NBIO) ("Nascent Biotech", "Nascent", or the "Company"), a clinical-stage biotechnology Company pioneering the development of monoclonal antibodies targeting treatment of various cancers and viral infections, is pleased to announce the completion of the Third cohort in dosing patients for its Phase I trial for Brain Cancer.

Advertisement
Advertisement